Business Context and Reporting Period
This Form 8-K is a current report filed by Onconova Therapeutics, Inc. (not Traws Pharma, Inc., as indicated in the metadata) on October 15, 2018, regarding events occurring on October 12, 2018. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on regulatory compliance status.
Material Changes
- Nasdaq Compliance Regained: The Company received notification from The Nasdaq Stock Market LLC that it has regained compliance with the minimum bid price requirement (Listing Rule 5550(a)(2)).
- Price Threshold Met: The Company's common stock maintained a minimum closing price of at least $1.00 per share for ten consecutive business days.
- Grace Period Conclusion: This compliance ends the 180-calendar-day grace period originally granted on May 7, 2018.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of new risks. The primary contingency addressed was the risk of delisting due to low stock price, which has been resolved as of the report date.
Investor Verification Checklist
- Verify the current trading price of Onconova Therapeutics, Inc. stock to ensure continued compliance with the $1.00 minimum bid price.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Review the attached Exhibit 99.1 (Letter from Nasdaq) for specific details on the compliance determination.